Skip to content

Remazolam toluenesulfonic acid was used in a large sample, multicentre, randomized, double-blind, parallel controlled clinical study of advantage mining in painless endoscopy

Remazolam toluenesulfonic acid was used in a large sample, multicentre, randomized, double-blind, parallel controlled clinical study of advantage mining in painless endoscopy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039582
Enrollment
Unknown
Registered
2020-11-01
Start date
2020-11-05
Completion date
Unknown
Last updated
2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless endoscopy

Interventions

1:Remazolam

Sponsors

Sichuan Provincial Academy of Medical Sciences & Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are going to have painless endoscopy; 2. Patients aged 18-80 years old, regardless of gender; 3. 18 < BMI < 30 kg/m2; 4. The American Association of anesthesiologists (ASA) was classified as I-III.

Exclusion criteria

Exclusion criteria: 1. Patients with hypotension < 80/50 mm Hg; 2. Heart rate < 50 beats/min; 3. Acute inflammation of respiratory tract within 2 weeks without cure; patients with severe metabolic diseases such as heart, brain, lung, liver, kidney and diabetes mellitus; previous myocardial infarction, severe myocardial ischemia, severe atrioventricular block; 4. Those who may or have had difficult airways or have a history of recovery from abnormal surgical anesthesia; 5. Patients with obvious electrolyte disorders such as hyperkalemia; 6. Long-term use of immunosuppressive agents such as hormones or patients with a history of adrenocortical suppression; 7. People known to be allergic to emulsions and opioids; 8. Concurrent use of other sedative and analgesic drugs before and after surgery (including injection, oral administration and use of relevant Chinese patent medicines); 9. Suspected abuse of narcotic analgesics or sedatives; 10. Those who have neuromuscular system diseases, psychiatric diseases and other uncooperative and unable to communicate.

Design outcomes

Primary

MeasureTime frame
Sedation success rate;

Secondary

MeasureTime frame
Time to adequate sedation;Sedation recovery time;Incidence of hypotension;The incidence of treatment-related hypotension;the incidence of respiratory depression;

Countries

China

Contacts

Public ContactMengchang Meng

Sichuan Provincial Academy of Medical Sciences & Sichuan Provincial People's Hospital

447924425@qq.com+86 18140049936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026